153 related articles for article (PubMed ID: 24297060)
1. Antibody-based magnetic nanoparticle immunoassay for quantification of Alzheimer's disease pathogenic factor.
Kim CB; Choi YY; Song WK; Song KB
J Biomed Opt; 2014 May; 19(5):051205. PubMed ID: 24297060
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
3. Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings.
Sabbagh MN; Shi J; Lee M; Arnold L; Al-Hasan Y; Heim J; McGeer P
BMC Neurol; 2018 Sep; 18(1):155. PubMed ID: 30257642
[TBL] [Abstract][Full Text] [Related]
4. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
5. Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimer's Disease: Present and future applications.
Reale M; Gonzales-Portillo I; Borlongan CV
Brain Res; 2020 Jan; 1727():146535. PubMed ID: 31669827
[TBL] [Abstract][Full Text] [Related]
6. Fabrication of an antibody-aptamer sandwich assay for electrochemical evaluation of levels of β-amyloid oligomers.
Zhou Y; Zhang H; Liu L; Li C; Chang Z; Zhu X; Ye B; Xu M
Sci Rep; 2016 Oct; 6():35186. PubMed ID: 27725775
[TBL] [Abstract][Full Text] [Related]
7. Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study.
Bermejo-Pareja F; Antequera D; Vargas T; Molina JA; Carro E
BMC Neurol; 2010 Nov; 10():108. PubMed ID: 21047401
[TBL] [Abstract][Full Text] [Related]
8. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
[TBL] [Abstract][Full Text] [Related]
9. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.
Schauer SP; Mylott WR; Yuan M; Jenkins RG; Rodney Mathews W; Honigberg LA; Wildsmith KR
Alzheimers Res Ther; 2018 Nov; 10(1):118. PubMed ID: 30486870
[TBL] [Abstract][Full Text] [Related]
10. Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids.
Galozzi S; Marcus K; Barkovits K
Expert Rev Proteomics; 2015 Aug; 12(4):343-54. PubMed ID: 26153725
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-related biomarkers for Alzheimer's disease.
Andreasen N; Zetterberg H
Curr Med Chem; 2008; 15(8):766-71. PubMed ID: 18393845
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
[TBL] [Abstract][Full Text] [Related]
13. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
[TBL] [Abstract][Full Text] [Related]
14. A novel approach for Aβ₁₋₄₀ quantification using immuno-PCR.
Hashimoto M; Aoki M; Winblad B; Tjernberg LO
J Neurosci Methods; 2012 Apr; 205(2):364-7. PubMed ID: 22327103
[TBL] [Abstract][Full Text] [Related]
15. Competitive electrochemical immunoassay for detection of β-amyloid (1-42) and total β-amyloid peptides using p-aminophenol redox cycling.
Liu L; He Q; Zhao F; Xia N; Liu H; Li S; Liu R; Zhang H
Biosens Bioelectron; 2014 Jan; 51():208-12. PubMed ID: 23962708
[TBL] [Abstract][Full Text] [Related]
16. A sandwich immunoassay for detection of Aβ(1-42) based on quantum dots.
Pi J; Long Y; Huang N; Cheng Y; Zheng H
Talanta; 2016; 146():10-5. PubMed ID: 26695227
[TBL] [Abstract][Full Text] [Related]
17. Magnetite/Ceria Nanoparticle Assemblies for Extracorporeal Cleansing of Amyloid-β in Alzheimer's Disease.
Kim D; Kwon HJ; Hyeon T
Adv Mater; 2019 May; 31(19):e1807965. PubMed ID: 30920695
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
19. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
[TBL] [Abstract][Full Text] [Related]
20. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
